STAR DIAMOND CORPORATION ANNOUNCES FIRST QUARTER 2025 RESULTS
SASKATOON, SK, May 13, 2025 /CNW/ - Star Diamond Corporation ("Star Diamond" or the "Company") reports that unaudited financial results for the quarter ended March 31, 2025, will be filed today on SEDAR+ and may be viewed at www.sedarplus.ca once posted. (In thousands of Canadian dollars, except common share or per share amounts or as otherwise noted).
Overview
Star Diamond is a Canadian natural resource company focused on exploring and evaluating Saskatchewan's diamond resources. Star Diamond holds a 100% interest in the Fort à la Corne Project, (FALC Project, which includes the Star – Orion South Diamond Project, or the "Project"). These properties are in central Saskatchewan, near established infrastructure, including paved highways and the electrical power grid, which provide significant advantages for future possible mine development.
The Company also holds a 100% interest in the exploration and evaluation properties and assets of the Buffalo Hills Diamond Project (the "BH Project") located approximately 400 kilometres northwest of Edmonton, Alberta, Canada (see " Corporate Developments").
Fort à la Corne mineral properties
The Company currently holds a 100% interest in certain Fort à la Corne ("FALC") kimberlites (see March 26, 2024, news release: Star Diamond Corporation completes acquisition of Rio Tinto's 75% interest in Fort à la Corne Joint Venture) including the Star and Orion South Kimberlites. The FALC mineral properties are located in the Fort à la Corne Provincial Forest, 60 km east of Prince Albert, Saskatchewan. Highway 55, located to the north of the Project, connects Prince Albert with several towns located directly north of FALC to the town of Nipawin, east of FALC. Highway 6 runs north south and is located to the east of FALC.
Recent activities relating to the Star - Orion South Diamond Project and Fort à la Corne mineral properties
The Revised Mineral Resources estimate (see July 24, 2024 news release: Star – Orion South Diamond Project Revised Mineral Resources Estimate) will now be incorporated into a re-optimized open pit mine plan for the Project, which will include a re-evaluation of Mineral Reserves and an economic assessment based thereon. It is anticipated that this work will be completed during 2025-26 and will result in an updated Pre-feasibility Study including a revised statement of Mineral Reserves for the Project, if warranted, and an economic assessment based thereon.
Effective January 1, 2025, the Company has outsourced the Chief Financial Officer ("CFO") to Mr. Carmelo Marrelli, replacing Mr. Rick Johnson.
In January 2025, the Company disposed of its remaining share position in Wescan Goldfields Inc. ("Wescan") for gross proceeds of $114.
On February 18, 2025 and February 27, 2025, Star Diamond closed a non-brokered private placement (the "Offering") of convertible debentures (the "Debentures") to raise aggregate gross proceeds of $335 and $230, respectively, which resulted in total gross proceeds of $565. The Debentures bear simple interest at a rate of 8% per annum and are convertible into common shares of the Company in certain circumstances, including upon a qualified offering to raise aggregate gross proceeds in excess of $2,000. Pursuant to the closing of both tranches of the Offering, the Company issued an aggregate combined total of 28,250,000 share purchase warrants ("Warrants"), being one Warrant for each $0.02 principal amount of Debentures purchased. Each Warrant is exercisable to acquire one common share of the Company at an exercise price of $0.06 for a period of 2 years from the closing. In connection with the Offering, Mr. Mason, CEO of the Company, purchased Debentures in the aggregate principal amount of $25. Ms. Lisa Riley, director of the Company, has purchased Debentures in the aggregate principal amount of $20.
On February 27, 2025, the Company announced the resignation of George Read as Senior Vice President Corporate Development effective February 28, 2025) and his appointment as a Senior Technical Advisor.
Buffalo Hills mineral properties
The Company holds a 100% interest in the exploration and evaluation properties and assets of the Buffalo Hills (BH) Project. Located approximately 400 kilometres northwest of Edmonton, Alberta, Canada, the BH Project includes 21 mineral leases covering 4,800 hectares and is a significant and accessible field of diamond-bearing kimberlites, with similarities to the Company's Fort á la Corne kimberlites. The BH Project is located in the Buffalo Hills Kimberlite District, which contains at least 38 individual kimberlite bodies, of which 26 kimberlites are diamond-bearing and a number of which outcrop at surface. Exploration on these kimberlites started in 1996, and small parcels of diamonds have been collected from various exploration programs on many of those considered most prospective.
Quarter End Results
For the three months ended March 31, 2025, the Company recorded a net loss of $966 or $0.00 per share (2024 – net loss of $886 or $0.00 per share). The increase in net loss was primarily due to the following:
Exploration and evaluation expenditures increased to $467 in 2025 (2024 - $289). Exploration and evaluation expenditures incurred during 2025 were primarily due to security and maintenance, continued diamond analyses, and test work for the FALC Project. due to increased depreciation of property, plant and equipment. In 2025, exploration and evaluation expenditures also included $225 of depreciation of property, plant and equipment (2024 - $1).
Unwinding of discount of environmental rehabilitation provision increased to $66 in 2025 (2024 - $nil).
Corporate development decreased to $13 in 2025 (2024 - $138) due to reduced marketing and publications issued in 2025.
On March 31, 2025, the Company had $321 (December 31, 2024 - $164) in cash and cash equivalents and a working capital deficit (excess of current liabilities over current assets) of $1,002 (2024 – working capital deficit of $1,017). The decrease in working capital deficit was a result of proceeds received from convertible debentures and sale of shares in Wescan Goldfields Inc., offset by net cash used in operating activities. In 2025, the Company initiated the following cost reductions:
We have moved our head office to a smaller area in the same building resulting in a 70% drop in our office lease payments;
All marketing and consulting contracts have been paused;
The Board agreed to forgo cash compensation until such time as the Company is on better financial footing; and
Certain management/employee functions will be reduced or eliminated.
A budget has been prepared for the completion of the PFS of $3,000 which is subject to the completion of a financing.
However, the ability of the Company to continue as a going concern and fund its expenses in an orderly manner will require additional forms of financing. There can be no assurance that the Company will succeed in obtaining additional financing, now or in the future. Failure to raise additional financing on a timely basis could cause the Company to suspend its operations and planned activities.
March 31, 2025 and 2024 is summarized as follows:
(1) Basic and diluted.
Summary of Quarterly Result
(1) Basic and diluted.
Outlook
Fort à la Corne mineral properties
Star Diamond's technical team will focus on the technical investigation and evaluation of the Star – Orion South Diamond Project, with the goal of a future development decision. The initial work was completed in 2024 with a revised Mineral Resource estimate for the Star – Orion South Diamond Project, which will form the foundation of an updated Prefeasibility Study ("PFS"). The PFS will enable a Feasibility Study, on which a production decision can be based.
Buffalo Hills mineral properties
Management continues to review the recent results from the diamond valuation and typing analysis with a view to possible work programs and a potential path forward for the asset. A more detailed update on activities at Buffalo Hills will be provided as it becomes available.
About Star Diamond Corporation
Star Diamond is a Canadian natural resource company focused on exploring and evaluating Saskatchewan's diamond resources. Star Diamond holds a 100% interest in the Fort à la Corne Project, (FALC Project, which includes the Star – Orion South Diamond Project, or the "Project"). These properties are in central Saskatchewan, near established infrastructure, including paved highways and the electrical power grid, which provide significant advantages for future possible mine development.
The Company also holds a 100% interest in the exploration and evaluation properties of the Buffalo Hills Diamond Project (the "BH Project") located approximately 400 kilometres northwest of Edmonton, Alberta, Canada (see " Corporate Developments").
Technical Information
All technical information in this MD&A has been prepared under the supervision of Mark Shimell, VP Exploration, Professional Geoscientist in the Province of Saskatchewan, who is the Company's "Qualified Person" under NI 43-101.
Caution Regarding Forward-looking Statements
This press release contains "forward-looking statements" and/or "forward-looking information" (collectively, "forward-looking statements") within the meaning of applicable securities legislation. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate" or "believes", or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results, "may", "could", "would", "will", "might" or "will be taken", "occur" or "be achieved" or the negative connotation thereof. All statements, other than statements of historical fact, are forward-looking statements.
These forward-looking statements are based on Star Diamond's current beliefs as well as assumptions made by and information currently available to Star Diamond and involve inherent risks and uncertainties, both general and specific. Risks exist that forward-looking statements will not be achieved due to a number of factors including, but not limited to, statements regarding Rio Tinto Canada, the Company's ability to obtain financing to further the exploration, evaluation and/or development of exploration and evaluation properties in which the Company holds interest, the economic feasibility of any future development projects, developments in world diamond markets, changes in diamond prices, risks relating to fluctuations in the Canadian dollar and other currencies relative to the US dollar, the impact of changes in the laws and regulations regulating mining exploration, development, closure, judicial or regulatory judgments and legal proceedings, operational and infrastructure risks and the additional risks described in Star Diamond's most recently filed Annual Information Form, and annual and interim MDA.
Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. In addition, forward-looking statements are provided solely for the purpose of providing information about management's current expectations and plans and allowing investors and others to get a better understanding of our operating environment. Accordingly, readers should not place undue reliance on forward-looking statements.
Forward-looking statements in this news release are made as of the date hereof and Star Diamond assumes no obligation to update any forward-looking statements, except as required by applicable laws.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
6 minutes ago
- Cision Canada
LABRADOR IRON ORE ROYALTY CORPORATION (TSX: LIF) - RIO TINTO RELEASES IOC PRODUCTION AND SALES INFORMATION
TORONTO, July 16, 2025 /CNW/ - Rio Tinto released its operations review for the second quarter ending June 30, 2025, which included Iron Ore Company of Canada (IOC) production and sales information. Specifically, Rio Tinto announced that in the second quarter of 2025, IOC had total saleable iron ore production of 4.24 million tonnes, comprised of 2.23 million tonnes of pellets and 2.01 million tonnes of concentrate for sale (CFS). Rio Tinto also announced that IOC had total iron ore sales in the second quarter of 2025 of 4.53 million tonnes, comprised of 2.35 million tonnes of pellets and 2.17 million tonnes of CFS. Comparisons to prior quarters and Rio Tinto's commentary on the changes can be found in Rio Tinto's quarterly operational report which is posted on their website. Please note that the IOC sales tonnages are calculated slightly differently for the Labrador Iron Ore Royalty Corporation's (LIORC) royalty. Rio Tinto's full year production guidance for IOC remains unchanged at 16.5 to 19.4 million tonnes. LIORC will be releasing its full second quarter report after the market close on August 6, 2025. About Labrador Iron Ore Royalty Corporation The Corporation holds a 15.10% equity interest in IOC directly and through its wholly-owned subsidiary, Hollinger-Hanna Limited, and receives a 7% gross overriding royalty on all iron ore products produced, sold and shipped by IOC and a 10 cent per tonne commission on all iron ore products produced and sold by IOC. Forward-Looking Statements This report may contain "forward-looking" statements that involve risks, uncertainties and other factors that may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Words such as "may", "will", "expect", "believe", "plan", "intend", "should", "would", "anticipate" and other similar terminology are intended to identify forward-looking statements. These statements reflect current assumptions and expectations regarding future events and operating performance as of the date of this report. Forward-looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such results will be achieved. A number of factors could cause actual results to vary significantly, including iron ore price and volume volatility; the performance of IOC; market conditions in the steel industry; fluctuations in the value of the Canadian and U.S. dollar; mining risks that cause a disruption in operations and availability of insurance; disruption in IOC's operations caused by natural disasters, severe weather conditions and public health crises, including the COVID-19 outbreak; failure of information systems or damage from cyber security attacks; adverse changes in domestic and global economic and political conditions; changes in government regulation and taxation; national, provincial and international laws, regulations and policies regarding climate change that further limit the emissions of greenhouse gases or increase the costs of operations for IOC or its customers; changes affecting IOC's customers; competition from other iron ore producers; renewal of mining licenses and leases; relationships with indigenous groups; litigation; and uncertainty in the estimates of reserves and resources. A discussion of these factors is contained in LIORC's annual information form dated March 11, 2025 under the heading, "Risk Factors". Although the forward-looking statements contained in this report are based upon what management of LIORC believes are reasonable assumptions, LIORC cannot assure investors that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this report and LIORC assumes no obligation, except as required by law, to update any forward-looking statements to reflect new events or circumstances. This report should be viewed in conjunction with LIORC's other publicly available filings, copies of which can be obtained electronically on SEDAR+ at


Vancouver Sun
6 minutes ago
- Vancouver Sun
Cheaper generic Ozempic is coming to Canada after Novo Nordisk fails to maintain patent in this country
In what Science magazine has dubbed 'Novo Nordisk's Canadian Mistake,' Ozempic is soon to come off patent in Canada, opening the door to cheaper generic copycats, after the drug giant reportedly failed to pay a few hundred dollars in annual fees to maintain the patent rights before the weight-loss drug became a blockbuster seller. As Science reported, a patent, once lapsed, can't be restored. Novo Nordisk will continue to hold its U.S. patent until 2032. Ozempic was already the third most prescribed drug in Canada last year with 7,390,000 prescriptions dispensed, a 17 per cent increase over 2023, according to drug analytics research firm IQVIA. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. Several applications for generic semaglutide, the active compound in Novo Nordisk's injectable drugs Ozempic and Wegovy, are now before Health Canada. Last week, a U.S. telehealth service announced plans to expand into Canada next year and offer generic semaglutide at a significant discount. Richard Saynor, the head of Sandoz, a global leader in generic and biosimilar drugs, told Endpoint News in June that his company has filed for approval for a generic semaglutide in Canada once Novo Nordisk's patent exclusivity expires 'sometime in Q1 next year.' Canada is the globe's second-biggest semaglutide market, Saynor told Endpoint News. 'You gotta ask why. I don't think Canadians are disproportionately large. There's clearly a dynamic, like insulin, with cross-border business,' he said. Americans with diabetes have crossed into Canada to buy insulin at much lower prices. Ozempic and Wegovy cost about $5,000 per year. If money is no longer a factor, if chemically-identical drugs are cheaper and more affordable, 'that's going to change the calculus for many people,' said Justin Lehmiller, a senior research fellow at Indiana University's Kinsey Institute and co-author of a new survey exploring the impact that weight-loss drugs — formally known as GLP-1 agonists — are having on dating and intimacy. The survey of 2,000 single Americans (aged 18 to 91) led by Kinsey with found eight per cent reported having used a GLP-1 medication for weight loss in the past year. Among the GLP-1 users, 16 per cent said exes had reached out to reconnect, 14 per cent said they were getting more matches on dating apps and 12 per cent said they were going on more dates. The drugs seemed to be doing more to booster 'online dating success' for men than for women, the researchers said. 'Some of the studies and research that I've seen suggest that men only match one in 100 times on dating apps where for women, it's more like one in 10,' Lehmiller said. 'An attractiveness boost for men, which often accompanies using these drugs, could translate into a much bigger impact for them in the world of dating.' Men, however, were nearly twice as likely to women to say they feared being judged or shamed for taking Ozempic or other GLP-1 drugs. 'There are some masculinity concerns that are tied up in this,' said Lehmiller, a social psychologist. Men might worry about being accused of cheating, he said. 'It might be viewed as a sign of weakness for turning to a drug as opposed to losing weight through 'hard work.'' About half of the GLP-1 users also said the medications impact their sex lives, in both positive and negative ways: 18 per cent said their sexual desire increased, while 16 per cent said it dropped. Sixteen per cent said their sexual function improved; 12 per cent said it worsened. It's a nuanced picture, Lehmiller said. 'These drugs seem to be affecting different people in different ways.' 'And I think that makes sense: There is a lot of variability in the side effects people experience on these drugs.' More side effects might mean more negative impact on intimacy, he said. The drugs have also been associated with a slightly higher risk o f erectile dysfunction and testosterone deficiency in men taking semaglutide for obesity compared to men not taking the drug. About one in five in the dating survey said the drugs are creating more stigma against being overweight. 'Changing standards of attractiveness might be creating more pressure for people to look a certain way or use these medications,' Lehmiller said. A study published this week in the Canadian Medical Association Journal found 32.7 per cent of adults in Canada (10.6 million people) were obese in 2023, an eight per cent jump over 2009. Generic versions of semaglutide won't be as cheap as Aspirin. They'll still require a doctor's prescription, said Dr. Hertzel Gerstein, an endocrinologist and professor in McMaster University's department of medicine. 'Like all drugs it's a powerful drug that can have side effects and people need to be instructed on the proper way to take the drug, what to expect and what to do.' 'Is it possible that more people would be willing to pay out of pocket if they don't have insurance coverage for the drug? Sure, if it's cheaper,' Gerstein said. 'There may be more demand for it. People need to understand the risks and benefits.' Taken once a week by injection, Ozempic and Wegovy work by mimicking a hormone — glucagon-like peptide-1 — the small intestine releases when people eat. GLP-1 tricks the body into thinking it's full. It works on the brain to reduce appetite and interest in continuing to eat, and works on the stomach to slow how fast it empties so that food lingers in the stomach longer. Semaglutide has been studied extensively, Gerstein said. The amount of weight lost is related to the dosage: the higher the dose, the more weight dropped. In people with type 2 diabetes, the drug can reduce the need for insulin, or the dosage. 'But most importantly these drugs unequivocally reduce the future risk of serious health outcomes, including heart attacks, strokes, death from cardiovascular causes' and heart failure symptoms when used long-term, 'in the two- to five-year window of time,' Gerstein said. A major analysis published earlier this year based on health data from more than two million Americans veterans with diabetes found that, compared to more traditional drugs, GLP-1 use was associated with a reduced risk of substance use (alcohol, cannabis, stimulants and opioids), psychotic disorders such as schizophrenia, seizures, several respiratory conditions and neurocognitive diseases like Alzheimer's and dementia. The magnitude of the associated benefits — about a 10 to 20 per cent reduction for most outcomes — was modest, according to a background release, though the researchers said they don't 'negate' the potential value of the drugs. There were, however, several drawbacks, including an increased risk of gastrointestinal disorders (nausea, vomiting, diarrhea), low blood pressure, fainting, arthritic disorders, kidney disorders and drug-induced pancreatitis associated with GLP-1 drugs compared to usual care. Nothing is guaranteed, Gerstein said. 'I always tell patients we don't know exactly what it'll do in you. And weight loss, if it's going to happen, usually takes a month or two to start' and plateaus at around eight months. People don't lose weight indefinitely. 'There's definitely a plateau. You do not keep losing weight,' he said. The drugs yield an average weight loss of around 15 per cent, and weight can also rebound rapidly once the drugs are stopped. Ozempic has been approved in Canada for diabetes but is often used 'off label' for obesity. Wegovy has been approved for obesity. In an email to National Post, Novo Nordisk, the only current company in Canada with Health Canada-approved products containing semaglutide, said 'all intellectual property decisions are carefully considered at a global level. 'Periods of exclusivity for pharmaceutical products end as part of their normal lifecycle and generic treatments may become available over time.' 'Currently, no Health Canada-approved generic versions of semaglutide exist and we cannot speculate on other manufacturers' plans,' the company said. National Post Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our newsletters here .


Edmonton Journal
6 minutes ago
- Edmonton Journal
Cheaper generic Ozempic is coming to Canada after Novo Nordisk fails to maintain patent in this country
In what Science magazine has dubbed 'Novo Nordisk's Canadian Mistake,' Ozempic is soon to come off patent in Canada, opening the door to cheaper generic copycats, after the drug giant reportedly failed to pay a few hundred dollars in annual fees to maintain the patent rights before the weight-loss drug became a blockbuster seller. Article content As Science reported, a patent, once lapsed, can't be restored. Novo Nordisk will continue to hold its U.S. patent until 2032. Article content Article content Ozempic was already the third most prescribed drug in Canada last year with 7,390,000 prescriptions dispensed, a 17 per cent increase over 2023, according to drug analytics research firm IQVIA. Article content Article content Several applications for generic semaglutide, the active compound in Novo Nordisk's injectable drugs Ozempic and Wegovy, are now before Health Canada. Last week, a U.S. telehealth service announced plans to expand into Canada next year and offer generic semaglutide at a significant discount. Article content Richard Saynor, the head of Sandoz, a global leader in generic and biosimilar drugs, told Endpoint News in June that his company has filed for approval for a generic semaglutide in Canada once Novo Nordisk's patent exclusivity expires 'sometime in Q1 next year.' Article content Canada is the globe's second-biggest semaglutide market, Saynor told Endpoint News. 'You gotta ask why. I don't think Canadians are disproportionately large. There's clearly a dynamic, like insulin, with cross-border business,' he said. Americans with diabetes have crossed into Canada to buy insulin at much lower prices. Article content Article content Ozempic and Wegovy cost about $5,000 per year. If money is no longer a factor, if chemically-identical drugs are cheaper and more affordable, 'that's going to change the calculus for many people,' said Justin Lehmiller, a senior research fellow at Indiana University's Kinsey Institute and co-author of a new survey exploring the impact that weight-loss drugs — formally known as GLP-1 agonists — are having on dating and intimacy. Article content The survey of 2,000 single Americans (aged 18 to 91) led by Kinsey with found eight per cent reported having used a GLP-1 medication for weight loss in the past year. Article content Among the GLP-1 users, 16 per cent said exes had reached out to reconnect, 14 per cent said they were getting more matches on dating apps and 12 per cent said they were going on more dates. The drugs seemed to be doing more to booster 'online dating success' for men than for women, the researchers said.